key: cord-1030409-jh81u2oo
authors: Fraissé, Megan; Logre, Elsa; Pajot, Olivier; Mentec, Hervé; Plantefève, Gaëtan; Contou, Damien
title: Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study
date: 2020-06-02
journal: Crit Care
DOI: 10.1186/s13054-020-03025-y
sha: 998f1d1b1c06e08dee769944b94329560b0ebbce
doc_id: 1030409
cord_uid: jh81u2oo

nan

Patients admitted to the intensive care unit (ICU) for coronavirus disease 2019 (COVID-19), following an infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seem to have an increased risk of thrombotic events (TE), both arterial and venous [1] [2] [3] . Even in the absence of high level of evidence, some centers have consequently modified their pharmacological thromboprophylaxis strategy toward intermediate or full-dose (therapeutic) preemptive anticoagulation (rather than prophylactic dosing) for routine care of COVID-19 patients [2, 4] , exposing them to a higher risk of hemorrhagic events (HE).

Our aim was to assess the rates and to describe each TE and HE occurring in critically ill COVID-19 patients admitted to our ICU.

We retrospectively analyzed data from patients admitted to our 41-bed COVID-19 ICU between March 6 and April 22, 2020. All patients received usual (prophylactic) or full-dose (therapeutic) anticoagulation according to their risk factors for thrombosis [4] . All TE (venous or arterial) diagnosed during ICU stay were collected, except central venous catheter related thrombosis and hemodialysis filter thrombosis. TE were investigated only in case of clinical suspicion, and not in a routine manner. All significant (interruption of anticoagulation and red blood cell transfusion, surgical intervention or death) HE were collected.

During the study period, 92 patients were admitted to our ICU for acute respiratory failure related to SARS-CoV-2 pneumonia. Main demographic and clinical characteristics are detailed in the Table 1 . At the time of analysis (May 6), 37 of them (40%) experienced a total of 39 TE including 31 venous (79%) and 8 arterial (21%) thrombosis, and 19 of them (21%) experienced a total of 22 HE during their ICU stay. Distributions of each TE and HE are detailed in the Fig. 1 .

Median days between ICU admission and TE and between first COVID-19 symptoms and TE were 9 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and 17 [12-28], respectively. There was no difference regarding clinical characteristics between patients with or without a TE, except from D-dimer levels and prothrombin time (Table 1) . Among patients with an HE, 16 (n = 16/19, 84%) received fulldose anticoagulation, including 8 (50%) without a confirmed TE. All HE required interruption of anticoagulation, 3 (14%) were fatal 1 (2 intra-cranial, 1 deep muscle), 14 (64%) required red blood cells transfusion, and 5 (24%) required bronchoscopy or gastroscopy. Only one of the 15 (7%) anti-Xa activity performed the day of HE was overdosed.

We herein report on a 40% rate of TE in critically ill patients with COVID-19, mostly venous TE. This rate is in accordance with previous series [1, 2] . However, it is lower than the 69% rate reported by Llitjos et al. who performed a systematic screening with Doppler ultrasound [5] . As previously reported [2] , PE was the leading cause of thrombosis in our cohort. As there is a growing interest in chest CT scan as a diagnostic tool for SARS-CoV-2 pneumonia [6] , performing a systematic pulmonary angiography may constitute a relevant strategy.

Noteworthy, we report on a 21% rate of significant HE, most of them occurring in patients with full-dose anticoagulation. As half of these patients were treated with full-dose preemptive anticoagulation without a confirmed TE, we must be cautious about our thromboprophylaxis strategy with daily reassessment of its Table 1 Characteristics of 92 critically ill COVID-19 patients who developed (n = 37, 40%) or not (n = 55, 60%) a thrombotic event during ICU stay (*at the time of analysis (May 6, 2020); data for 91 patients as one patient was lost to follow-up) All indication. Moreover, it is interesting to note that fulldose anticoagulation did not prevent some patients from developing a TE. The retrospective monocenter design of our study implies numerous limitations. Nevertheless, we reported on a high rate of TE and HE in ICU COVID-19 patients highlighting the necessity to adapt our thrombo-prophylaxis strategy as well as our TE screening strategy. 

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Traitement anticoagulant pour la prevention du risque thrombotique chez un patient hospitalise avec covid-19 et surveillance de l'hemostase propositions du GIHP et du GFHT

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Sensitivity of chest CT for COVID-19: comparison to RT-PCR

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Authors' contributions MF, DC, and GP are responsible for the conception and design. All the authors were responsible for the data acquisition, analysis, and interpretation. All authors read, critically reviewed, and approved the final manuscript. DC takes responsibility for the paper as a whole.

Availability of data and materials The dataset used and analyzed for the current study is available from the corresponding author on reasonable request.

This study was conducted in accordance with the amended Declaration of Helsinki and was approved by the Institutional Review Board (CE 20-39) of the French Intensive Care Society.

Not applicable

The authors declare that they have no competing interests.Received: 18 May 2020 Accepted: 25 May 2020